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Abstract
The biological significance of the almost constant presence of macrophages in the tumoral microenvironment is an issue debated
by several authors. The major difficulty in understanding the role played by tumor-associated macrophages (TAMs) in tumor
progression is due to the contrasting effects of TAMs found in different studies. In addition, there is a limited information on which
of the many biological activities expressed by TAMs are critical in inducing stimulatory or inhibitory effect on tumor growth.
The aim of our study was: (a) to explore to what extent cyclo-oxygenase-2 (COX-2) in TAMs associated with human melanoma
is expressed at different stages of tumor progression; and (b) to explore whether COX-2 expression in TAMs is stimulated by
melanoma cells. In order to answer this question, we determined COX-2 positive TAMs associated with cutaneous melanocytic
nevi, in situ, invasive and metastatic melanoma. In addition, we investigated whether COX-2 is expressed in peritoneal thioglycollate-
elicited macrophages after co-cultivation with murine B16 melanoma cells. We found that COX-2-positive TAMs, as revealed by
immunohistochemical analysis, were rare in common nevi and “dysplastic nevi”, but present in a high percentage in in situ and thin
melanoma. COX-2-positive TAMs were also found in more advanced tumors and metastatic melanoma, although at a significantly
lower percentage in these latter. The in vitro protocol revealed that COX-2 was expressed in peritoneal macrophages upon contact
with B16 murine melanoma cells, but not with normal murine fibroblasts. On the whole, the results of in vivo and in vitro studies
suggest that COX-2 expressed in TAMs appears to act as an effective biomarker of melanoma progression, and melanoma cells
themselves might stimulate COX-2 in macrophages.
© 2007 Elsevier Inc. All rights reserved.
Keywords: Cyclo-oxygenase-2 (COX-2); Tumor-associated macrophages (TAMs); Human melanomas; Immunoistochemical analysis; F10-M3
murine melanoma cells; Thioglycollate-elicited murine macrophages
1. Introduction
Tumor associated macrophages (TAMs), besides their well-documented tumoricidal activity [1,2], may promote
tumor cell invasiveness and metastatic diffusion under certain conditions [3–6]. These contrasting effects might be
∗ Corresponding author. Tel.: +39 055 4598207; fax: +39 055 4598900.
E-mail address: lido.calorini@unifi.it (L. Calorini).
1098-8823/$ – see front matter © 2007 Elsevier Inc. All rights reserved.
doi:10.1016/j.prostaglandins.2007.03.003
F. Bianchini et al. / Prostaglandins & other Lipid Mediators 83 (2007) 320–328 321
explained on the basis of the different functions expressed by TAMs under the influence of signals generated by host
inflammatory cells as well as tumor cells themselves [7–9]. Among the various inflammatory mediators generated by
TAMs, a particular attention has been devoted to arachidonic acid metabolites, which are known to influence several
biological responses, involved in tumor progression [10], such as inflammatory and immune reactions, haemostasis
and angiogenesis [11]. COX-2, an inducible isoform of COX particularly expressed in various types of tumors [12–16],
largely contributes to the generation of tumoral arachidonic acid metabolites. This finding opened the way to inves-
tigating whether COX-2 might represent a target for inhibiting tumor growth by the use of appropriate inhibitors of
COX-2. Indeed, the incidence of human colorectal carcinoma [12,17–20], as well as the number and size of polyps in
Apc delta716 knockout mice [21] were reduced by treatment with aspirin, a typical inhibitor of COX. In spite of the
finding that COX-2 may be expressed in macrophages, it has not been yet clarified to what extent TAMs contribute to
the high level of COX-2 found in tumors, and, in particular, in malignant melanoma.
In this study, we determined COX-2-positive TAMs associated with human melanoma at different stages of pro-
gression. Our experimental material consisted in: 5 cutaneous melanocytic nevi (2 benign common acquired nevi and 3
so-called atypical, “dysplastic nevi”); 4 in situ melanoma; 11 invasive cutaneous melanoma representative of different
pT categories; and 7 metastatic melanoma (5 dermal/subcutaneous metastases, 1 lymph nodal and 1 lung metastases)
(from the archive of the Department of Human Pathology and Oncology, University of Florence). Histopathological
slides were reviewed for the presence of ulceration, histotype, Breslow thickness and Clark’s level.
We, also, investigated whether melanoma cells promoted the expression of COX-2 in macrophages by using an
in vitro experimental model, represented by co-cultures of B16 murine melanoma cells and thioglycollate-elicited
macrophages collected from the peritoneal cavities of syngeneic mice.
2. Materials and methods
2.1. Immunohistochemical analysis
Immunohistochemistry was carried out on 4 m-thick paraffin sections. All sections were deparaffined in Bio-Clear
(Bio-Optica, Mi, Italy) and hydrated with grade ethanol concentrations and water. To block endogenous peroxi-
dase activity, slides were treated with 3.0% hydrogen peroxidase in distilled water for 10 min. Antigen retrieval was
routinely performed by microwave pretreatment (Microwave MicroMED T/T Mega, Milestone, Bg, Italy) in TEC
(Tris–EDTA–citrate buffer pH 8) for 30 min. After blocking non-specific antigen with normal horse serum (UltraVi-
sion, Lab-Vision, Fremont, CA), serial sections from all specimens were analyzed with monoclonal antibody against
CD68 (clone PGM-1, Dako) and a monoclonal antibody against COX-2 (clone COX-229, Zymed, San Francisco, CA).
The primary antibody was used at a dilution 1:50 at room temperature for 1 h, followed by incubation with peroxidase
conjugated polymer (Chemmate Dako Envision Detection Kit rabbit-mouse) for 30 min. The reaction products were
visualized with 3-amino-9-ethylcarbazole (AEC, Lab-Vision) for 10 min. The nuclei were counterstained with Mayer’s
haematoxylin. For negative control, a slide was prepared from the same tissue block and a pre-immune serum was
used instead of the primary antibody. As positive control we used an intestinal adenocarcinoma specimen. The control
sections were treated in parallel with the samples in the same run.
COX-2 immunostaining in the cytoplasm of tumor cells was independently reviewed by two observers and semi-
quantitatively scored as − negative, + focal, ++ moderate, and +++ diffuse, as previously described [22]. The
number of CD68 positive cells and COX-2 positive TAMs was recorded by careful evaluation of serial sections from
each specimen (microscopic field at 400× magnification). The percentage of COX-2 positive CD68 cells was also
determined.
2.2. Cells and culture conditions
In the present study, we used a clone isolated from murine B16-F10 melanoma cells (F10-M3 cells) [23] and primary
cultures of murine skin fibroblasts isolated in our laboratory from C57Bl/6 mice. Cells were cultivated in Dulbecco’s
Modified Eagle Medium (DMEM 4500) supplemented with 10% fetal calf serum (FCS), at 37 ◦C in a 10% CO2
humidified atmosphere. Cells were propagated using a solution of trypsin–EDTA.
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2.3. Co-cultures of macrophages with tumor cells or normal fibroblasts
Macrophage cultures were established from peritoneal exudates collected from 6 to 8 week old C57Bl/6 mice,
that had been injected intraperitoneally with 1 ml of 3% thioglycollate broth (SIGMA) 3–4 days before, as previously
described [24]. Co-cultures were prepared by seeding tumor cells or normal skin fibroblasts on macrophage monolayers
at 1:1 ratio and at the density of 250 × 103 cells/cm2. Co-cultures were washed with PBS and then incubated for 24 h
in a medium containing 250 g/ml bovine serum albumin (BSA), at 37 ◦C in a 10% CO2 humidified atmosphere.
In some experiments, co-cultures were grown in a medium supplemented with murine recombinant IFN (25 U/ml)
(Peprotech) and LPS (10 ng/ml) (SIGMA), two classical agents of macrophage activation [25].
2.4. RNA isolation and polymerase chain reaction (PCR)
Total RNA was extracted from macrophages freed from tumor cells, tumor cells and fibroblasts using RNA total isola-
tion system (Promega), and the amount and purity of the RNA was determined spectrophotometrically. Complementary
cDNA was synthesized from 1 g of total RNA using 4 U/l of M-MLV reverse transcriptase (Promega). Aliquots of
5 l of the cDNA were used for PCR amplification. The specific primers used for identification of 2-microglobulin
and murine COX-2 were: 2-microglobulin (sense tgc-tat-cca-gaa-aac-ccc-tc; antisense gtc-atg-ctt-aac-tct-gca-gg)
[26], and COX-2 (AAC TCC CAT GGG TGT GAA GGG; antisense CCA AAG ATA GCA TCT GGA CGA G) [27].
All PCR reactions were conducted using 0.1 U/l of Go-Taq polymerase (Promega) and carried out on a Perkin Elmer
thermal cycler. Ten microliters of each PCR products were visualized by electrophoresis in a 2% agarose gel, containing
0.5 mg/ml of ethidium bromide. cDNA products were evaluated on the basis of a standard PCR marker (Promega).
2.5. Western blotting analysis
Cells were washed twice with ice cold PBS containing 1 mM Na4VO3. Cells were lysed in 100 l of cell lysis buffer
containing 20 mM Tris/HCl (pH 7.4), 150 mM NaCl, 100 mM HEPES, 1% Triton-X100, 10 mM glycerophosphate,
100 mM PMSF, 100 M AEBSF, 5 mM bestain, 2 mM leupeptin, 1 mM pepstatin, 80 M aprotinin, 1.5 mM E-64.
Aliquots of supernatants containing equal amounts of protein (65 g) in Laemmli buffer were separated on 10% (v/v,
SDS/PAGE gel). Transfer of fractionated proteins from the gel to a PVDF nitrocellulose membrane was carried out
using an electroblotting apparatus (Bio-Rad). Blots were blocked with 2.5% (w/v) bovine serum albumin (BSA) in T-
PBS (0.1%, v/v, Tween-20 in PBS) for 1 h at room temperature. Subsequently, membrane was probed at 4 ◦C overnight
with COX-2 rabbit anti mouse monoclonal antibody (BIOMOL) diluted 1:1000 with 2.5% (w/v) BSA in T-PBS. After
washing in T-PBS buffer, the membrane was incubated, for 1 h at room temperature, with horseradish peroxidase-
conjugated anti-rabbit IgG antibody (SIGMA), diluted 1:16,000 with 2.5% (w/v) BSA in T-PBS. Immunoreactive
bands were visualized by the ECL detection system (Amersham, USA).
2.6. Statistical analysis
The relationship between COX-2 expression and clinico-pathological variables was assayed by the two-tailed
Fisher’s exact test or by the two-tailed Pearson’s Chi-squared method. A p < 0.05 was considered statistically significant.
3. Results
3.1. In vivo investigation
COX-2 immunoreactivity was focally detected in adnexal structures, such as hair follicles and eccrine glands,
but absent in normal epidermis adjacent to either nevi or melanoma lesions. COX-2 was absent in melanocytes of
benign common nevi and “dysplastic nevi”, but expressed by melanoma cells of primary and metastatic lesions.
Immunoreactivity of melanoma cells for COX-2 did not correlate with thickness or any other clinico-pathological
variables of the lesions. As reported in Table 1 and shown in Fig. 1, a small percentage of TAMs (CD-68 positive
cells) expressed COX-2 in common nevi and “dysplastic nevi”, while high percentages of COX-2 positive TAMs were















Immunohistochemical analysis of COX-2 expression in melanoma at different stages of progression




CD68+ cellsd COX-2+ TAMsd COX-2+/ CD68+
cells in percente
1 28/f Neck CN − 31.8 2 6.2
2 41/f Neck CN − 28.4 0 0
3 34/m Trunk DN − 49 1 2.0
4 46/f Abdomen DN − 66.4 18.8 28.3
5 35/f Back DN − 48.6 1.2 2.4
6 84/m Back MIS SSM −/I + 51 40.3 79.0
7 68/m Trunk MIS SSM −/I − 22.4 12 53.5
8 54/f Shoulder MIS SSM −/I − 28 20.7 73.9
9 63/f Neck MIS SSM −/I + 23.2 18.8 81.0
10 74/m Back MM SSM 0.70/III Absent + 56 38 67.8
11 46/m Trunk MM SSM 0.60/III Absent − 84.6 62.2 61.2
12 60/m Shoulder MM SSM 0.20/II Absent + 77 50 64.9
13 30/f Shoulder MM SSM 0.65/III Absent ++ 87 75 57.7
14 62/f Arm MM SSMn 1.30/IV Absent − 60.6 0 0
15 72/m Back MM SSM 1.10/IV Absent + 66.4 0 0
16 57/f Back MM SSM 1.20/IV Absent ++ 61.6 40 64.9
17 79/f Arm MM SSM 1.90/IV Present + 83.6 25 29.9
18 54/m Temporal MM SSM 3.80/IV Present ++ 90.2 61.8 68.5
19 68/m Foot MM NM 5.00/IV Absent ++ 50 4 8
20 71/m Face MM SSM 3.50/IV Present ++ 69 42.3 61.3
21 57/m Arm Met − 18 0 0
22 89/f Leg Met +++ 39 3.2 8.2
23 75/f Leg Met − 17.4 0 0
24 82/m Trunk Met − 25 0 0
25 71/m Leg Met +++ 20.3 0 0
26 55/f Lymph node Met ++ 96 0 0
27 66/m Lung Met +++ 82 0 0
a CN: common acquired nevus; DN: dysplastic nevus; MIS: in situ melanoma; MM: primary malignant melanoma; Met: melanoma metastasis.
b SSM: superficial spreading melanoma; SSMn: superficial spreading melanoma arising on a nevus; NM: nodular melanoma.
c Staining: +++ diffuse; ++ moderate; + focal; − negative expression.
d CD68+ cells and COX-2+ TAMs are mean of number of positive cells found in 5 areas (microscopic field: 0.16 mm2, at 400× magnification) of each specimen.
e COX-2+ CD68 cells are expressed as percentage of COX-2+ TAMs / CD68 cells.
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Fig. 1. Immunohistochemical analysis of COX-2 expression in human melanoma cells and in TAMs in a representative common nevus (A), dysplastic
nevus (B), in situ melanoma (level I) (C), thin melanoma (levels II and III) (D), advanced melanoma (level IV) (E) and metastatic melanoma (F).
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in situ and thin melanoma (radial growth phase of melanoma, levels I–III) than in advanced tumors (vertical growth
phase of melanoma, level IV) and metastatic melanoma (relation significantly different at p = 0.001). COX-2 positive
TAMs were found to be preferentially distributed at the periphery of tumors, rather than in the context of the tumoral
mass. Moreover, in lesions containing the highest number of COX-2 positive TAMs, these latter were found to cluster
at the advancing edge of the tumor.
3.2. In vitro investigation
As shown in Fig. 2 (panels A and B), mouse thioglycollate-elicited macrophages expressed mRNA and protein for
COX-2 after stimulation with IFN/LPS. mRNA and protein for COX-2 were also expressed in elicited macrophages co-
cultivated with F10-M3 murine melanoma cells. This effect was still more evident in elicited macrophages co-cultivated
with F10-M3 melanoma cells in the presence of IFN/LPS. mRNA and protein for COX-2 were not expressed in F10-
Fig. 2. Change in mRNA (panel A) and protein (panel B) for COX-2 in thioglycollate-elicited macrophages (M) co-cultivated with F10-M3 murine
melanoma cells, in the presence or in the absence of IFN/LPS.
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Fig. 3. Expression of mRNA for COX-2 in thioglycollate-elicited macrophages (M) co-cultivated with normal murine fibroblasts.
M3 cell cultures as well as in tumor cells removed from the co-cultures (Fig. 1, panels A and B). As shown in Fig. 3,
macrophages did not expressed COX-2 when they were co-cultivated with normal murine fibroblasts, indicating that
COX-2 promoting activity of melanoma cells is rather specific. Moreover, COX-2 was not expressed by macrophages
co-cultivated with tumor cells in transwell chambers as well as by macrophages grown in tumor cell-conditioned
media (data not shown). This finding rules out the possibility that soluble factors play a role in COX-2 expression by
macrophages co-cultivated with tumor cells.
4. Discussion
Our study revealed that in situ and thin melanoma contained a particular high percentage of COX-2-positive TAMs,
which declined in advanced and metastatic melanoma. COX-2-positive TAMs were preferentially located at the invasive
front of the tumor, an observation, also, reported for TAMs associated with colon carcinoma [28]. Our study, also,
showed that COX-2 expression in melanoma cells at a different stage of progression was not different. This finding
is consistent with a recent publication by Denkert et al. (2001) [22]. Moreover, in vitro experiments demonstrated
that murine inflammatory macrophages expressed COX-2 (mRNA and protein) upon contact with syngeneic F10-
M3 murine melanoma cells. The specificity of this phenomenon is demonstrated by the finding that COX-2 was not
expressed in macrophages co-cultivated with normal murine fibroblasts.
In conclusion, our data suggest that COX-2 expressed in TAMs, and not in tumor cells, appears to act as an effective
biomarker of melanoma progression, and melanoma cells themselves might stimulate COX-2 in macrophages. The
biological relevance of this phenomenon is indicated by the particular high concentration of COX-2-positive TAMs
at the advancing edge of the early melanoma lesions, where remarkable interactions between macrophages and tumor
cells are possible [29]. However, it is difficult to identify the precise effect of the accumulation of COX-2-expressing
TAMs in in situ and thin melanoma. It is possible, that the high number of COX-2 positive TAMs might account for
the COX-2 over-expression that was reported in pre-malignant lesions, such as Barrett’s esophagus, oral leukoplakia,
gastric and cervical dysplasia [30], and colorectal polyps [31]. Moreover, an involvement of COX-2 in malignant
transformation is sustained by the finding that COX-2 inhibitors prevent the development of mammary tumors in
rat treated with 7,12-dimethylbenz(a)anthracene [32], and reduce the occurrence of colorectal adenomas in patients
with familial adenomatous polyposis [33–35]. PGE2, the main product of COX-2, is the more probable candidate in
promoting malignant properties associated with COX-2 expression. In fact, PGE2 was found to suppress proliferation
of T and B lymphocytes and activity of Natural Killer cells [36,37], which are essential for host defence against
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tumor progression. Therefore, COX-2 expressed in TAMs may provide an attractive therapeutic target for prevention
or treatment of melanoma.
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